SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/ accessed on May 2, 2015). ClinicalTrials. Treatment Phase Patient population N Status gov dentifier NVOLUMAB gemcitabine /cisplatin, pemetrexed /cisplatin, carboplatin /paclitaxel, bevacizumab maintenance, erlotinib or Nivolumab + sunitinib or pazopanib or bevacizumab or vs sunitinib Advanced NSCLC 412 Ongoing NCT01454102 Advanced untreated renal cell carcinoma Advanced renal cell carcinoma Previously untreated, advanced or metastatic renal cell carcinoma 175 NCT01472081 45 Ongoing NCT02210117 107 0 Ongoing NCT02231749 Advanced melanoma 160 Ongoing NCT01621490 Vaccine (Class Peptides) + Montanide SA 51VG + Resected stage C/ V nivolumab or 85 Ongoing NCT01176474 + nivolumab Vaccine (Class Peptides) + Montanide SA 51VG + nivolumab Sequential nivolumab and followed by nivolumab pilimumab +/- nivolumab followed by dabrafenib/ trametinib or opposite sequence pilimumab vs. nivolumab vs. nivolumab + Unresectable Stage or V Malignant Unresectable Stage /V Metastatic to the Brain Previously Untreated, Unresectable or Metastatic Advanced BRAF V600 mutation-positive melanoma Previously Untreated Unresectable or Metastatic 136 150 140 NCT01024231 NCT01176461 NCT01783938 148 Ongoing NCT02320058 150 300 915 NCT01927419 NCT02224781 NCT01844505 NATURE REVEWS CANCER
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Dabrafenib + trametinib followed by + nivolumab at progression vs. +nivolumab followed by dabrafenib + trametinib at progression or lirilumab (anti-kr antibody) Nivolumab + Urelumab Nivolumab + pilimumab Nivolumab + HPV-16 Vaccination GVAX pancreas vaccine, cyclophosphamide + CRS- 207 +/- nivolumab Nivolumab vs nivolumab + vs bevacizumab in solid tumours Nivolumab + varlilumab (anti CD27 antibody) Nivolumab + anti-lag-3 monoclonal antibody Expande d access - Advanced BRAFV600 Mutant Untreated, Unresectable or Metastatic Younger Patients With Recurrent or Refractory Solid Tumours or Sarcomas Lymphoma and Multiple Myeloma Advanced/Metastatic Solid Tumours and B-cell Non- Hodgkin Lymphoma Patients With Advanced HV Associated Solid Tumours Patients With HPV-16- Positive ncurable Solid Tumours Recurrent and Metastatic Microsatellite High Colon Cancer Previously Treated Metastatic Pancreatic Adenocarcinoma 300 Ongoing NCT02224781 - Ongoing NCT02186249 204 Ongoing NCT02304458 315 Ongoing NCT01592370 200 Ongoing NCT02253992 42 28 NCT02408861 NCT02426892 96 Ongoing NCT02060188 94 Ongoing NCT02243371 Glioblastoma 440 Ongoing NCT02017717 Triple-negative breast cancer, gastric cancer, pancreatic adenocarcinoma, small cell lung cancer and bladder cancer Non-Small Cell Lung Cancer,, Colorectal, Ovarian or Head and Neck Squamous Cell Carcinoma. 410 Ongoing NCT01928394 190 Ongoing NCT02335918 Advanced Solid Tumours 168 Ongoing NCT01968109 NATURE REVEWS CANCER
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Nivolumab + lirilumab (anti-kr antibody) Nivolumab + nterleukin-21 Nivolumab + NCB24360 (DO inhibitor) PEMBROLZUMAB carboplatin /paclitaxel, pemetrexed /carboplatin, bevacizumab maintenance, erlotinib, gefitinib or BCG Pembrolizumab and High Dose FN-alfa2b Pembrolizumab +Talimogene Laherparepvec Pf- 05082566 (4-1BB Agonist) NCB024360 (DO inhibitor) Pegylated nterferon Alfa- 2b or pilimumab ADXS31-142 (viral vector + PSA) +/- Pembrolizumab Peginterferon Alfa-2b AM0010 (Pegylated L-10) + Pembrolizumab / chemotherapy / pazopanib ic9-gd2 (CAR) T Cell Lymphocytes + Cyclophosphamide + Fludarabine + pembrolizumab PDLZUMAB Pidilizumab + Dendritic Cell renal cell carcinoma vaccine Advanced Solid Tumours 162 Ongoing NCT01714739 Solid Tumours 33 Completed NCT01629758 Select Advanced Cancers 221 Ongoing NCT02327078 - Advanced NSCLC 308 Ongoing NCT02039674 High Risk Superficial Bladder Cancer Locally/Regionally advanced/recurrent (neoadjuvant) Untreated, Unresected, Stage B to VM1c 15 30 NCT02324582 NCT02339324 110 Ongoing NCT02263508 Advanced Solid Tumours 45 Ongoing NCT02179918 Selected Solid Tumours 120 Ongoing NCT02178722 Advanced (MEL) and Renal Cell Carcinoma Metastatic castrationresistant prostate cancer 343 Ongoing NCT02089685 52 Ongoing NCT02325557 Advanced 32 Ongoing NCT02112032 Advanced solid tumours 135 Ongoing NCT02009449 Relapsed or refractory neuroblastoma Renal Cell Carcinoma 44 38 Ongoing NCT01822652 NCT01441765 Sipuleucel +/- pidilizumab Rand. Castration-resistant 57 Ongoing NCT01420965 NATURE REVEWS CANCER
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) +/- cyclophosphamide metastatic prostate cancer Multiple myeloma, Pidilizumab + Dendritic following Stem Cell Cell myeloma Vaccine Transplantation MPDL3280A NCB024360 (DO inhibitor) RO7009789 (CD40 agonist) MPDL3280A +MOXR0916 (OX40 agonist) or interferonalpha RO6895882 (engineered L-2v + antibody against carcinoembryonic antigen) MED4736 MED4736 + Gefitinib or AZD9291 or selumetinib + docetaxel or followed by sequential MED4736 Tremelimumab +/- MED4736 ADXS11-001 or MED4736 or ADXS11 001 + MED4736 MED4736 vs vs + MED4736 + MED4736 vs MED4736 + vs standard of care MED4736 +/- MED4736 + Motolimod (TLR-8 agonist) + Pegylated Liposomal Previously Treated Stage B or V Non-Small Cell Lung Cancer Metastatic or locally advanced solid tumours Locally advanced and/or Locally advanced or Locally advanced and/or 35 NCT01067287 80 Ongoing NCT02298153 160 Ongoing NCT02304393 360 NCT02410512 200 Ongoing NCT02174172 75 NCT02350673 Non-small cell lung cancer 301 Ongoing NCT02000947 Locally advanced or metastatic NSCLC Previously Treated Locally Cervical or HPV+ Head & Neck Cancer Recurrent or Metastatic Recurrent or Metastatic Recurrent gastric or gastroesophageal junction adenocarcinoma Recurrent, Platinum- Resistant Ovarian Cancer 40 Ongoing NCT02179671 164 Ongoing NCT02262741 66 Ongoing NCT02291055 240 720 NCT02319044 NCT02369874 174 Ongoing NCT02340975 53 NCT02431559 NATURE REVEWS CANCER
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Doxorubicin Mogamulizumab (anti- CCR4) +MED4736 or MED4736 +AMP-514 (anti-pd-1) MED4736 + MED4736 + NCB024360 (DO inhibitor) MED4736 + Tremelimumab +/- MED4736 Advanced solid tumours 108 Ongoing NCT02301130 Advanced Malignancies 160 Ongoing NCT02118337 Solid tumours 102 Ongoing NCT01975831 Selected advanced solid tumours 157 Ongoing NCT02318277 Advanced solid tumours 210 Ongoing NCT02261220 Japanese with advanced solid malignancies 22 Ongoing NCT02141347 Abbreviations: CAR: chimeric antigen receptor. CCR4; chemokine receptor 4. DO: indoleamine dioxygenase-1. TLR: toll-like receptor. NATURE REVEWS CANCER